Investment Opportunity for an Innovative Treatment for Prader-Willi Syndrome

epm Therapeutics

US-based biopharmaceutical company focused on proprietary fully synthetic small molecule therapeutics to treat diseases with high unmet medical needs

1 EPM301 Lead Program

- EPM301 is first-in-class oral therapy for PWS
- Robust nonclinical package demonstrating potential disease modifying impact on PWS including Hyperphagia, Anxiety, Depression, Daytime sleepiness
- FDA and EMA ODD and FDA RPDD and Patent Protection through 2042

2 Prader-Willi Syndrome

- Rare genetic condition ~ prevalence at birth; 1/15,000-30,000 worldwide
- Significant unmet need as no approved treatments
- Challenging management of hyperphagia leading to obesity and other clinical complications

3 Opportunity

- **EPM is seeking $3 million to fund IND-enabling program and FDA IND filing with multiple value inflection opportunities on the horizon**
- Leadership team with extensive experience in biotech growth and development success